Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401

An Extension Study to Evaluate the Long-Term Safety, Tolerability, and Clinical Activity of IMO-8400 in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia Who Completed Study 8400-401

An extension study for patients who complete 24 weeks of IMO-8400 on study 8400-401.

Patients who had no evidence of disease progression or toxicity while participating in study 8400-401 (NCT02092909) will continue to receive IMO-8400 until disease progression, adverse event or the investigator deems the goals of extended treatment with IMO-8400 have been met.

Inclusion Criteria:

• Completed 24 weeks of treatment in Protocol 8400-401

Exclusion Criteria:

• Grade 3 (or higher) adverse event assessed as treatment-related at any time during the course of treatment under Protocol 8400-401.
• Has evidence of disease progression under Protocol 8400-401.
• Has received other anti-cancer therapies other than IMO-8400 since enrolling in Protocol 8400-401.